Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

The intelligence a $25K terminal charges for — the day it breaks, in your market, at a fraction of the price.

The funding market, moving in real timeBook a DemoChoose your plan
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Executive ChangeItem 5.02 · 8-KLOW RiskPositive

AbCellera Biologics Inc.

Filed: Jun 1, 2026VancouverCIK: 0001703057
Watch CompanyView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

AbCellera Biologics appointed Victor Sandor as an independent director on June 1, 2026. This board expansion reflects the company's commitment to strengthening governance, though the appointment is routine and carries minimal financial or operational impact.

Key Takeaways

Victor Sandor appointed as new independent director, effective June 1, 2026

Board confirmed Dr. Sandor meets NASDAQ independence criteria under Corporate Governance Guidelines

2 more takeaways

Related Filings (3)

3 more filings from AbCellera Biologics Inc. in the last 90 days

Filing Overview

Form Type8-K
Filing DateJun 1, 2026
Item5.02
CategoryExecutive Change
CIK0001703057
Accession #abcl-20260601
Risk LevelLOW
SentimentPositive
Signalinformational
Topics
board change

What This Means

A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.
View Full Filing on SEC.govBrowse More Filings